Imunon Inc. Common Stock (IMNN)
FairStock Score: 37/100 — MIXED
Key Financials
| Current Price | $1.24 |
| Market Cap | $7M |
| P/E Ratio | -0.42 |
| ROE | -429.72% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I look at Imunon as a clinical-stage biotech with a Phase 3 ovarian-cancer program, not an operating business with revenue. In fiscal year 2023 ended 2023-12-31, it reported net income of -$19.5 million and diluted EPS of -$2.16. In fiscal year 2024 ended 2024-12-31, net income was -$18.6 million and diluted EPS -$16.94. In fiscal year 2025 ended 2025-12-31, net income improved to -$14.5 million and diluted EPS -$6.83. More recently, in fiscal Q1 2026 ended 2026-03-31, net income was -$4.2 million; in fiscal Q2 2026 ended 2026-06-30, net income was -$2.8 million. Revenue is n/a in all filed periods. So there is no earnings base and no moat I can identify; the asset is intellectual property and trial hope.
In plain English: Imunon is a small clinical-stage biotechnology company working on immunotherapies and vaccines, mainly a treatment for advanced ovarian cancer. It has no reported revenue, loses money, and burns cash, so the business looks financially weak today. At $1.07, the stock is not cheap in the usual sense because there are no profits to compare it with; its value depends mostly on whether its experimental treatments succeed.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer